Zealand Pharma A/S (CPH: ZEAL)
Denmark
· Delayed Price · Currency is DKK 886.50
+15.00 (1.72%)
Aug 30, 2024, 4:59 PM CET
Zealand Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 367.97 | 342.79 | 103.99 | 108.55 | 192 | 41.33 | Upgrade
|
| Revenue Growth (YoY) | 301.39% | 229.65% | -4.20% | -43.47% | 364.52% | 8.84% | Upgrade
|
| Cost of Revenue | 714.45 | 688.1 | 614.04 | 10.97 | - | 0.42 | Upgrade
|
| Gross Profit | -346.47 | -345.31 | -510.06 | 97.58 | 192 | 40.92 | Upgrade
|
| Selling, General & Admin | 269.62 | 215.93 | 269.51 | 298.21 | 222.39 | 67.88 | Upgrade
|
| Research & Development | 104.62 | - | - | 581.51 | 595.85 | 561.42 | Upgrade
|
| Other Operating Expenses | - | - | 48.27 | - | - | -0.44 | Upgrade
|
| Operating Expenses | 374.24 | 215.93 | 306.54 | 879.72 | 818.24 | 628.86 | Upgrade
|
| Operating Income | -720.72 | -561.24 | -816.6 | -782.14 | -626.24 | -587.94 | Upgrade
|
| Interest Expense | -21.44 | -25.83 | -57.79 | -4.09 | -49.31 | -3.21 | Upgrade
|
| Interest & Investment Income | 66.12 | 45.32 | 6.54 | 0.04 | 2.02 | 6.29 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.23 | -9.71 | 25.6 | 36.52 | - | 5.52 | Upgrade
|
| Other Non Operating Income (Expenses) | -50.15 | -1.99 | 11.01 | -3.47 | - | -0.19 | Upgrade
|
| EBT Excluding Unusual Items | -724.97 | -553.44 | -831.24 | -753.14 | -673.53 | -579.52 | Upgrade
|
| Merger & Restructuring Charges | - | - | -19.1 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 19.41 | -8.84 | 2.34 | -3.57 | - | 2.85 | Upgrade
|
| Asset Writedown | -11 | -11 | -1.46 | -2.17 | - | - | Upgrade
|
| Other Unusual Items | - | -135.59 | -122.58 | - | - | - | Upgrade
|
| Pretax Income | -716.56 | -708.87 | -972.04 | -758.89 | -673.53 | -576.68 | Upgrade
|
| Income Tax Expense | -4.55 | -5.13 | -6.43 | -3.95 | -4.81 | -5.14 | Upgrade
|
| Earnings From Continuing Operations | -712 | -703.74 | -965.61 | -754.94 | -668.71 | -571.54 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -236.53 | -263.21 | -178.02 | - | Upgrade
|
| Net Income | -712 | -703.74 | -1,202 | -1,018 | -846.73 | -571.54 | Upgrade
|
| Net Income to Common | -712 | -703.74 | -1,202 | -1,018 | -846.73 | -571.54 | Upgrade
|
| Shares Outstanding (Basic) | 60 | 57 | 46 | 43 | 38 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 60 | 57 | 46 | 43 | 38 | 34 | Upgrade
|
| Shares Change (YoY) | 16.42% | 22.49% | 7.77% | 11.73% | 13.51% | 10.12% | Upgrade
|
| EPS (Basic) | -11.82 | -12.44 | -26.02 | -23.75 | -22.07 | -16.91 | Upgrade
|
| EPS (Diluted) | -11.82 | -12.44 | -26.02 | -23.75 | -22.07 | -16.91 | Upgrade
|
| Free Cash Flow | -524.37 | -436.91 | -954.02 | -1,234 | -713.76 | -430.49 | Upgrade
|
| Free Cash Flow Per Share | -8.70 | -7.72 | -20.65 | -28.79 | -18.60 | -12.74 | Upgrade
|
| Gross Margin | -94.16% | -100.74% | - | 89.89% | 100.00% | 99.00% | Upgrade
|
| Operating Margin | -195.86% | -163.73% | -785.30% | -720.56% | -326.16% | -1422.45% | Upgrade
|
| Profit Margin | -193.49% | -205.30% | -1156.05% | -937.99% | -441.00% | -1382.77% | Upgrade
|
| Free Cash Flow Margin | -142.50% | -127.46% | -917.45% | -1136.94% | -371.75% | -1041.52% | Upgrade
|
| EBITDA | -713.21 | -554.72 | -729.52 | -768.57 | -583.54 | -574.26 | Upgrade
|
| EBITDA Margin | -193.82% | -161.83% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 7.51 | 6.51 | 87.08 | 13.57 | 42.69 | 13.68 | Upgrade
|
| EBIT | -720.72 | -561.24 | -816.6 | -782.14 | -626.24 | -587.94 | Upgrade
|
| EBIT Margin | -195.86% | -163.73% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.